Fujifilm Invests $200 Million to Expand Global Cell Therapy Manufacturing Capabilities

Written By Kathleen Otto

Fujifilm Corporation, under the leadership of President and CEO Teiichi Goto, is making a strategic investment of $200 million in two subsidiaries to significantly enhance global cell therapy contract development and manufacturing (CDMO) capabilities. This investment will specifically support FUJIFILM Cellular Dynamics, Inc., a prominent developer and manufacturer of human induced pluripotent stem cells (iPSC) and iPSC-derived cells, and the California site of FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) in biologics and advanced therapies.

Kathleen Otto
Previous

Nanoscope Therapeutics Expands Leadership Team, Appoints Glenn Sblendorio as Chairman of the Board
Next

FDA Grants Breakthrough Status to Johnson & Johnson's TAR-200 for High-Risk Bladder Cancer